Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Eyepoint Pharmaceuticals Inc
PV3BCurrent price
10.09 EUR
-0.35 EUR (-3.31%)
Last closed
10.76 USD
Company
eyepointpharma.com
ISIN
US30233G2093
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
793 759 168 USD
Yield for 12 month
+48.38 %
1Y
3Y
5Y
10Y
15Y
PV3B
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Address: 480 Pleasant Street, Watertown, MA, United States, 02472
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
34.9 USDP/E ratio
–Dividend Yield
–Current Year
+46 018 000 USD
Last Year
+41 404 000 USD
Current Quarter
+10 524 000 USD
Last Quarter
+9 477 000 USD
Current Year
+41 386 000 USD
Last Year
+33 078 000 USD
Current Quarter
+9 788 000 USD
Last Quarter
+8 076 000 USD
Key Figures PV3B
1 year
3 years
5 years
10 years
EBITDA
-114 583 800 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-31.39 %
PEG Ratio
–
Return On Equity TTM
-74.68 %
Wall Street Target Price
34.9 USD
Revenue TTM
45 713 000 USD
Book Value
4.09 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-30.8 %
Dividend Yield
–
Gross Profit TTM
26 948 000 USD
Earnings per share
-1.78 USD
Diluted Eps TTM
-1.78 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-226.57 %
Dividend Analytics PV3B
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PV3B
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
09.12.2020
Dividend Date
09.12.2020
Stock Valuation PV3B
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
10.6528
Price Sales TTM
15.752
Enterprise Value EBITDA
-11.4934
Price Book MRQ
3.4768
Financials PV3B
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PV3B
For 52 weeks
5.86 USD
30.99 USD
50 Day MA
9.5 USD
Shares Short Prior Month
8 929 577
200 Day MA
14.36 USD
Short Ratio
15.84
Shares Short
9 171 397
Short Percent
20.09 %
BeatStart